Modification of contact lenses via metal-organic frameworks for glaucoma treatment
Alexey V. Yaremenko , Roman O. Melikov , Nadezhda A. Pechnikova , Iaroslav B. Belyaev , Alina Ringaci , Tamara V. Yaremenko , Aziz B. Mirkasymov , Alexandr A. Tamgin , Vladislav I. Rodionov , Sofya M. Dolotova , Grigory A. Plisko , Evgeny D. Semivelichenko , Anna S. Rogova , Albert R. Muslimov , Arina S. Ivkina , Dmitry Yu. Ivkin , Valery P. Erichev , Sergey M. Deyev , Sergey E. Avetisov , Yongjiang Li , Hai-Jun Liu , Ivan V. Zelepukin
Aggregate ›› 2024, Vol. 5 ›› Issue (5) : e586
Modification of contact lenses via metal-organic frameworks for glaucoma treatment
The prevention of blindness from glaucoma requires multiple treatments to lower intraocular pressure. Here, human contact lenses are modified with highly porous metal-organic frameworks with sustained release of brimonidine for prolonged glaucoma treatment. Various metal-organic frameworks were screened for their attachment to lenses, loading with brimonidine, and drug-release properties. Optimized therapeutic ocular lenses conjugated with MIL-101(Cr) frameworks maintain optical transparency and power. Coating of lenses with MIL-101(Cr) nanoparticles reduced brimonidine washout with tears and ensured a gradual and localized release of the drug into the eyeball through the cornea. The hybrid lenses provided a 4.5- fold better decrease in eye pressure, compared by area under the curve (AUC) value to a commercially available brimonidine tartrate solution. Therapeutic lenses did not induce any notable eye irritation or corneal damage in vivo. The newly developed hybrid lenses are expected to provide a robust platform for the therapy and prevention of various ocular diseases.
brimonidine / contact lenses / drug delivery / glaucoma / intraocular pressure / metal-organic frameworks / nanoparticles
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
WHO, World Report on Vision, Licence: CC BY-NC-SA 3.0 IGO, World Health Organization, Geneva 2019. |
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
2024 The Author(s). Aggregate published by SCUT, AIEI, and John Wiley & Sons Australia, Ltd.
/
| 〈 |
|
〉 |